Glaukos (GKOS) Q1 2026 Earnings Transcript

Glaukos reported record Q1 consolidated net sales of $150.6 million, up 41% year over year, and raised full-year 2026 revenue guidance to $620 million-$635 million from $600 million-$620 million. U.S. glaucoma sales rose 58% to $93.5 million, led by about $54 million of iDose TR sales, while corneal health sales reached $21.3 million including early Epioxa revenue of $17.7 million. Management also highlighted gross margin of 84% (+120 bps) and improving access milestones for Epioxa, including a product-specific J-code effective July 1, 2026.

Analysis

The core setup is not just a beat-and-raise; it is a transition from “product launch story” to “workflow adoption story,” and that matters for how the market will underwrite the next 2-3 quarters. iDose is starting to look less like a one-product reimbursement win and more like a platform that can compound via reimplantation, combination procedures, and expanding MAC coverage, which should steepen the revenue curve even if stand-alone volume eventually normalizes. The second-order effect is that commercial leverage should improve faster than top-line growth once the reimbursement base hardens, because the company is now spending into pull-through rather than pure education.

Epioxa is earlier and messier, but that is precisely where the hidden upside sits: the misc-code period creates visible operational friction that is likely depressing near-term sell-side models more than the actual end-state demand will justify. The key signal is not near-term billed cases; it is the acceleration in site coverage and payer pathway creation, which suggests the launch is becoming supply-constrained by process rather than by clinician conviction. That usually means the first real inflection comes when the J-code goes live and specialty pharmacy/buy-and-bill workflows normalize, likely creating a sharper-than-expected step-up in late Q3 into Q4.

The main risk is not lack of clinical demand; it is pacing risk. If the company over-earnestly ramps DTC, field force, and access spending before reimbursement friction clears, margin expansion could pause for 1-2 quarters even as revenue inflects, and investors may misread that as slowing adoption. A second risk is that the market overestimates how quickly corneal health converts from “coverage in place” to “routine utilization,” since the bottleneck is now administrative throughput, not physician enthusiasm.

Consensus may still be underestimating two things: first, the durability of iDose adoption outside the original early-adopter MACs, and second, the size of the keratoconus market once detection improves. If management is right that the addressable eye count is materially larger than historical treated volumes, then Epioxa is not just a replacement product but a market-expansion asset. That makes the stock a plausible multi-quarter rerating candidate, but only if investors are willing to look through the launch noise and focus on access normalization plus evidence accumulation.

Key Decisions for Investors

• Go long GKOS on any pullback over the next 1-2 weeks; use a 3-6 month horizon. Risk/reward favors upside if the market starts discounting Q3/Q4 acceleration from the J-code and broader iDose reimbursement base.
• Buy GKOS Jan-2027 call spreads to capture the re-rating from Epioxa normalization and iDose evidence accumulation. The thesis is that launch friction suppresses near-term expectations while the earnings power expands into 2027.
• Pair trade: long GKOS / short a basket of slower-growing ophthalmology or med-tech names with mature reimbursement profiles. The relative alpha case is strongest if investors begin paying for growth acceleration rather than current-period margin purity.
• If already long, hedge with short-dated GKOS puts into the next 1-2 quarters only if you think launch execution will create near-term margin volatility. The risk is timing, not thesis; use hedges rather than outright exits.
• Avoid chasing after a single strong quarter in the market open; wait for confirmation that Q2 misc-code friction is manageable and that coverage expansion continues. The better entry is when the stock trades on launch confusion, not when consensus fully catches up.